Brief: Fresenius Says FDA And EMA Accepted Vedolizumab Biosimilar Candidate For Review
31/07/2026 07:28
BRIEF-Fresenius Says FDA And EMA Accepted Vedolizumab Biosimilar Candidate For Review July 31 (Reuters) - Fresenius SE & Co KGaA FREG.DE:
FRESENIUS SE - ANNOUNCES FDA AND EMA ACCEPTANCE FOR REVIEW OF VEDOLIZUMAB BIOSIMILAR CANDIDATE
Further company coverage: FREG.DE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Fresenius SE & Co. KGaA
See all newsFresenius lifts 2026 expectations after strong Q3 (updated)
Healthcare firm Fresenius Q3 revenue rises on Kabi growth; lifts outlook
Brief: Fresenius Sees FY26 EBIT Margin Above 11.5%
Brief: Fresenius SE Q3 Revenue EUR 5,803 Million
Fresenius signs biosimilars pipeline agreement with WuXi Biologics (updated)